Opening of the permeability transition pore (PTP), a high-conductance mitochondrial channel, causes mitochondrial dysfunction with Ca 2+ deregulation, ATP depletion, release of pyridine nucleotides and of mitochondrial apoptogenic proteins. Despite major efforts, the molecular nature of the PTP remains elusive. A compound library screening led to the identification of a novel high affinity PTP inhibitor (Ro 68-3400), which labeled a ∼32 kDa protein that was identified as isoform 1 of the voltage-dependent anion channel (VDAC1) 
Introduction
The mitochondrial permeability transition pore (PTP) plays an important role in Ca 2+ homeostasis, bioenergetics and cell death. Although the role of the PTP in pathophysiology in vivo has been firmly established [1] [2] [3] , and despite detailed functional characterization [4] , the molecular components forming the PTP remain undefined [5] .
Early studies demonstrated that the permeability transition induced by sulfhydryl reagents is not observed in mitoplasts, suggesting that inner membrane permeability changes require the outer mitochondrial membrane as well [6] . Several lines of evidence suggest that the outer membrane protein involved in PTP formation may be VDAC: (i) purified VDAC incorporated into planar phospholipid bilayers forms channels with a pore diameter of 2.5-3.0 nM whose electrophysiological properties are strikingly similar to those of the PTP [7, 8] ; (ii) the VDAC channel properties change when activity is assessed in the presence of NADH, Ca 2+ or glutamate [9] [10] [11] , or after binding of hexokinase II [12, 13] , conditions that also modulate the activity of the PTP [14] [15] [16] ; (iii) chromatography of mitochondrial extracts on a cyclophilin D (CyP-D) affinity matrix allowed purification of VDAC and the adenine nucleotide translocase, which in the presence of CyP-D (the mitochondrial receptor for cyclosporin A, CsA) catalyzed CsA-sensitive permeabilization of liposomes to solutes [17] .
The idea that VDAC is a component of the PTP has been considerably reinforced by a recent study where a chemical library was screened for inhibitors of PTP-dependent swelling of rat liver mitochondria. A novel compound, spiro[cyclopen-
,11′-dihydro-3-methylene (Ro 68-3400) was identified that inhibits the PTP with high affinity [18] and labeling of mitochondria with [ 3 H]Ro 68-3400 revealed prominent reactivity of a membrane protein of ∼32 kDa [18] . The tracer was competitively displaced by unlabeled Ro 68-3400 and partial purification of the labeled protein led to identification of isoform 1 of the voltage-dependent anion channel (VDAC1) as the mitochondrial target of Ro 68-3400 [18] .
In order to further test whether VDAC1 is a component of the PTP, we have studied the properties of the PTP in mitochondria from VDAC1 −/− and wild-type, strain-matched mice.
Materials and methods

Compounds and chemicals
Ro 68-3400 was prepared at Hoffmann-La Roche Ltd., Basel, Switzerland. [ 3 H]Ro 68-3400 (65 Ci/mmol, 1 Ci = 37 Mbq) was kindly prepared by Dr. Thomas Hartung (Hoffmann-La Roche Ltd., Basel, Switzerland). Carbonylcyanide-p-trifluoromethoxyphenyl hydrazone (FCCP), CsA, N-ethylmaleimide (NEM), phenylarsine oxide (PhAsO) and ubiquinone (Ub) 0 were from Sigma.
Animals
VDAC1-deficient mice were generated by homologous recombination in embryonic stem cells followed by blastocyst microinjection, as previously described [19, 20] . The engineered mutation deletes exons 2-5, including the start codon, creating a null allele. Because of partial embryonic lethality in certain genetic backgrounds, the VDAC1 mutation was backcrossed onto the outbred strain CD1 and the resulting mice intercrossed to create VDAC1-deficient and wildtype littermate control mice. Genotyping was carried out by PCR, as described [21] . Mice were maintained and treated in accordance with an institutionally approved animal protocol.
Preparation of mouse liver mitochondria
Mitochondria were isolated from the livers of wild-type CD1 and VDAC1 −/− mice exactly as described previously for rat liver mitochondria [22] except that 10 ml of isolation medium per liver were used.
Mitochondrial swelling
Mitochondrial volume changes were determined from the changes in absorption at 545 nm with a Perkin Elmer λ10 spectrophotometer equipped with magnetic stirring and thermostatic control. The incubation conditions are described in the figure legends.
Western blot analysis
Eighty micrograms of total protein were separated on 12% SDSpolyacrylamide gels. The separated proteins were transferred to polyvinylidene difluoride membranes. Membranes were blocked in a solution of 500 mM NaCl, 20 mM Tris-HCl, 0.3% Tween 20, pH 7.4 containing 5% (v/v) skimmed milk for 1 h at room temperature and then incubated with a commercial monoclonal antibody specific for VDAC1 (mAb1, Calbiochem) [23] , or polyclonal antibodies specific for VDAC2 and VDAC3 as described in [20] . The secondary antibody used was peroxidase-conjugated anti-mouse IgG for mAb1 (1:5000 dilution) and anti-chicken IgG (1:10,000 dilution) for the polyclonal antibodies specific for VDAC2 and VDAC3, respectively. The membranes were developed using an ECL reaction and exposed to Kodak X-Omat films for 1-10 min.
Affinity labeling of mitochondria
Mitochondria (50-80 μg protein per sample) were incubated in the presence of 10 nM [
3 H]Ro 68-3400 in a final volume of 400 μl in 150 mM NaCl, 10 mM Pi pH 7.4 (phosphate buffered saline, PBS). After incubation for 15 min at 25°C , samples were centrifuged at 10,000×g. Samples were solubilized in sample buffer containing β-mercaptoethanol (30 min at 37°C) and subjected to SDSpolyacrylamide gel-electrophoresis (PAGE) on Tris-glycine mini-gels (12% polyacrylamide). After Coomassie Blue staining, gels were processed for fluorography by soaking in Amplify™ (Amersham Biosciences) for 1 h, drying and exposure to X-ray BioMax MS film with BioMax MS intensifying screens at −80°C for the appropriate times.
Hydroxyapatite chromatography
Mitochondria (about 5 mg protein in 5 ml) were labeled as described above with 10 nM [
3 H]Ro 68-3400 for 15 min at 25°C, and all the following steps were carried out at 4°C unless otherwise stated. After centrifugation, the labeled mitochondria were solubilized in 5 mM Tris-HCl pH 7.0, 1 mM EDTA. The vial with the extract was kept in an ice-water bath and sonicated at 35 W with a micro tip in a Fisher Sonic 300 instrument until the turbidity of the suspension disappeared. This suspension was centrifuged at 7000 × g to eliminate unbroken mitochondria and the supernatant was centrifuged at 100,000 × g for 20 min. The resulting pellet was solubilized in 1.2 ml 5 mM Tris-HCl, pH 7.0, 1 mM EDTA, 1% Triton TX-100 (buffer A). After 30 min on ice, the suspension was centrifuged at 20,000 × g for 10 min and the supernatant further processed.
The mitochondrial proteins were fractionated essentially as described in [24] with the following modifications. The supernatant was filtered through 0.22 μm filters (Millipore) and applied onto a ceramic hydroxyapatite Type-II 20 × 0.5 cm column (Amersham Biosciences Äkta FPLC purifier) equilibrated with buffer A at 25°C. The flow rate was set at 0.5 ml buffer A × min −1 and the flowthrough was collected. Subsequently, a gradient from 100% buffer A to 100% buffer B (1 M NaCl, 200 mM NaPi, 1% Triton X-100, pH 7.4) was applied. The radioactive 32 kDa band eluted between 55 and 65% buffer B and relevant fractions were pooled for further analysis. Proteins were precipitated by the addition of 4 volumes of ice-cold acetone. After 12 h at −20°C, proteins were collected by centrifugation at 20,000×g for 30 min at 4°C. The supernatants were removed and 20% trichloroacetic acid was added. After 30 min on ice, the proteins were collected by centrifugation at 20,000 × g for 30 min at 4°C. The supernatants were removed and the pellets washed with diethylether. After centrifugation at 20,000 × g for 30 min at 4°C, the pellets were washed with water and the final pellets were dried under vacuum. The supernatant of the final water wash was checked for radioactivity and no radioactivity was detected. Proteins were resuspended in standard Laemmli gel sample buffer and subjected to SDS-PAGE, Western blot analysis and autoradiography in parallel samples as described above.
Results and discussion
We compared the properties of the PTP in mitochondria from the liver of wild-type CD1 and of VDAC1 −/− mice. PTP opening was monitored as the decrease of absorbance of the mitochondrial suspension that follows mitochondrial swelling (Fig. 1) . After the addition of a permissive Ca 2+ pulse, PTP opening was induced with three different stimuli, i.e., the protonophore FCCP (traces a, a′), which causes pore opening through depolarization [25] ; PhAsO (traces b, b′), which causes pore opening through dithiol cross linking [26] ; and a relatively high concentration of NEM (c, c′), which causes pore opening by sensitizing it to oxidants [27] . Mouse mitochondria readily underwent the expected swelling response upon the addition of the PTP inducers, and the rate and extent of swelling (which was fully sensitive to CsA, results not shown) was indistinguishable in wild-type and VDAC1
−/− mitochondria. These experiments establish that the permeability transition can occur in the absence of VDAC1.
We next tested whether the PTP in VDAC1 −/− mitochondria could be inhibited by CsA, Ub0 and Ro 68-3400 (Fig. 2) . The inhibitory effects of CsA on the PTP is mediated by its interactions with CyP-D [28] [29] [30] through a mechanism that is clearly distinct from that of Ro 68-3400 [18] . Therefore, the finding that CsA inhibited the PTP with exactly the same affinity in wild-type and VDAC1 −/− mitochondria was not surprising (panel A). The unexpected finding was that both Ub0 and Ro 68-3400, which are presumed to act at the same site on VDAC1 [18] , displayed identical potencies at PTP inhibition in the VDAC1 −/− and wild-type mitochondria (panels B and C). In order to assess whether PTP inhibition correlated with reaction of the 32 kDa protein previously identified by affinity labeling [18] , liver mitochondria were treated with 10 nM [ 3 H]Ro 68-3400 after incubation with increasing concentrations of unlabeled Ro 68-3400 or Ub0 and subjected to SDS-PAGE and autoradiography. A radioactive protein of 32 kDa was detected in both wild-type and VDAC1 −/− mitochondria, whose binding could be competed by Ro 68-3400 at 10-100 nM and by Ub0 at 10-30 μM (Fig.  3) , i.e., the same concentrations of these compounds causing significant inhibition of the PTP [18, 31] . This finding clearly demonstrates that a protein other than VDAC1, but with similar electrophoretic mobility, is labeled by [ 3 H]Ro 68-3400 in mitochondria prepared from VDAC1 −/− mice. In line with this result is the fact that Ro 68-3400 had an inhibitory effect on Ca 2+ -induced swelling in VDAC1 −/− mouse liver mitochondria (Fig. 2) .
Three genes encode VDAC isoforms in mammals [32] and each isoform is able to form channels when incorporated into planar bilayers, albeit with somewhat different characteristics [33] . A reasonable explanation for the above findings could be that in the absence of VDAC1 other isoforms of the protein may take part in PTP formation. A Western blot analysis confirmed the absence of VDAC1 in liver mitochondria from VDAC1 −/− mice, and demonstrated that identical levels of VDAC2 and VDAC3 are expressed in wild-type and VDAC1 −/− mitochondria. In addition, the levels of protein capable of high-affinity modification by Ro 68-3400 were identical in VDAC1 −/− and wild-type mitochondria (Fig. 4) .
In order to establish whether the Ro 68-3400-reactive 32 kDa species of VDAC1 −/− mitochondria was VDAC2 and/ or VDAC3, we labeled mitochondria with 10 nM [ 3 H]Ro 68-3400 and subjected the membrane fraction to chromatography on hydroxyapatite after extraction with detergent. As shown in Fig. 5 , panel A, all the 3 VDAC isoforms present in wild-type mitochondria, as well as VDAC2 and VDAC3 present in VDAC1 −/− mitochondria (lane 1) were recovered in the flowthrough (lane 2), while none could be found in the fraction eluting at about 120 mM Pi (lane 3). Quite unexpectedly, the 32 kDa protein labeled by [ 3 H]Ro 68-3400 was absent in the VDAC-containing flowthrough fractions, while it was recovered in the 120 mM Pi-eluted fraction (Fig. 5, panel B) . The basis for the discrepancy between these findings and those of Cesura et al., who found the [ 3 H]Ro 68-3400-labeled species in the flowthrough fraction [18] is not obvious, but must lie in subtle differences in sample preparation that are currently under active investigation. Irrespective of the basis for this discrepancy, our ability to resolve the 32 kDa labeled species from all VDAC isoforms demonstrates that none of them can be the target for Ro 68-3400, consistent with the finding that this compound inhibits equally well the PTP in wild-type and VDAC1 −/− mitochondria. We are currently in the process of identifying the protein(s) labeled by [ 3 H]Ro 68-3400. So far, MALDI TOF-MS analysis of the labeled region did not demonstrate the presence of any of the proteins proposed to be implicated in the PTP, including the adenine nucleotide translocator.
Summary and conclusions
A considerable amount of experimental evidence suggests that outer membrane VDAC may take part in PTP formation [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] , an issue that was considerably strengthened by our identification of VDAC1 as the target for the high affinity inhibitor Ro 68-3400 [18] . Data in this manuscript indicate that the properties of the PTP in VDAC1 −/− mitochondria are identical to those of wild-type mitochondria; and that Ro 68-3400 does not bind to any of the mouse VDAC isoforms. These results demonstrate the VDACs are not the mitochondrial receptors for Ro 68-3400, but do not rule out that VDACs may be part of the PTP.
Mice missing VDAC1 and VDAC3 are viable but display isoform-specific phenotypes [34] , while the unconditional elimination of VDAC2 results in embryonic lethality [35] . Thus, as was the case for the present study, the involvement of specific VDAC isoforms in PTP function will be difficult to assess in these animals since any VDAC isoform may potentially compensate for the absence of any other isoform. The application of more advanced genetic approaches (e.g., loxP versions of individual VDAC genes or the use of siRNA) may allow the generation of reliable data. Until such studies are available, the involvement of VDAC in PTP formation remains an open question. 
